vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $20.6M, roughly 1.3× Entrada Therapeutics, Inc.). BCB BANCORP INC runs the higher net margin — -49.7% vs -84.4%, a 34.7% gap on every dollar of revenue. On growth, BCB BANCORP INC posted the faster year-over-year revenue change (13.1% vs -65.2%). BCB BANCORP INC produced more free cash flow last quarter ($34.9M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs 1.8%).
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
BCBP vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $20.6M |
| Net Profit | $-12.0M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | -106.0% |
| Net Margin | -49.7% | -84.4% |
| Revenue YoY | 13.1% | -65.2% |
| Net Profit YoY | -467.6% | -173.8% |
| EPS (diluted) | $-0.73 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | — | ||
| Q3 25 | $26.5M | — | ||
| Q2 25 | $25.2M | — | ||
| Q1 25 | $23.8M | $20.6M | ||
| Q4 24 | $23.1M | $37.4M | ||
| Q3 24 | $26.2M | $19.6M | ||
| Q2 24 | $20.4M | $94.7M | ||
| Q1 24 | $25.3M | $59.1M |
| Q4 25 | $-12.0M | — | ||
| Q3 25 | $4.3M | — | ||
| Q2 25 | $3.6M | — | ||
| Q1 25 | $-8.3M | $-17.3M | ||
| Q4 24 | $3.3M | $1.1M | ||
| Q3 24 | $6.7M | $-14.0M | ||
| Q2 24 | $2.8M | $55.0M | ||
| Q1 24 | $5.9M | $23.5M |
| Q4 25 | -71.9% | — | ||
| Q3 25 | 21.9% | — | ||
| Q2 25 | 19.9% | — | ||
| Q1 25 | -49.2% | -106.0% | ||
| Q4 24 | 19.9% | -15.7% | ||
| Q3 24 | 35.7% | -110.7% | ||
| Q2 24 | 19.5% | 56.4% | ||
| Q1 24 | 33.0% | 35.7% |
| Q4 25 | -49.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 14.2% | — | ||
| Q1 25 | -35.0% | -84.4% | ||
| Q4 24 | 14.1% | 3.0% | ||
| Q3 24 | 25.5% | -71.7% | ||
| Q2 24 | 13.8% | 58.1% | ||
| Q1 24 | 23.2% | 39.7% |
| Q4 25 | $-0.73 | — | ||
| Q3 25 | $0.22 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | $-0.51 | $-0.42 | ||
| Q4 24 | $0.17 | $-0.20 | ||
| Q3 24 | $0.36 | $-0.35 | ||
| Q2 24 | $0.14 | $1.55 | ||
| Q1 24 | $0.32 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $417.3M |
| Total Assets | $3.3B | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $67.8M | ||
| Q4 24 | — | $101.2M | ||
| Q3 24 | — | $78.0M | ||
| Q2 24 | — | $185.3M | ||
| Q1 24 | — | $68.4M |
| Q4 25 | $304.3M | — | ||
| Q3 25 | $318.5M | — | ||
| Q2 25 | $315.7M | — | ||
| Q1 25 | $314.7M | $417.3M | ||
| Q4 24 | $323.9M | $428.7M | ||
| Q3 24 | $328.1M | $422.4M | ||
| Q2 24 | $320.7M | $429.9M | ||
| Q1 24 | $320.1M | $269.4M |
| Q4 25 | $3.3B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.5B | $486.5M | ||
| Q4 24 | $3.6B | $526.3M | ||
| Q3 24 | $3.6B | $554.6M | ||
| Q2 24 | $3.8B | $582.0M | ||
| Q1 24 | $3.8B | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-38.5M |
| Free Cash FlowOCF − Capex | $34.9M | $-39.7M |
| FCF MarginFCF / Revenue | 133.3% | -192.9% |
| Capex IntensityCapex / Revenue | 4.0% | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | — | ||
| Q3 25 | $8.7M | — | ||
| Q2 25 | $10.3M | — | ||
| Q1 25 | $5.0M | $-38.5M | ||
| Q4 24 | $67.7M | $-31.6M | ||
| Q3 24 | $43.5M | $-24.3M | ||
| Q2 24 | $8.1M | $39.8M | ||
| Q1 24 | $8.3M | $-25.5M |
| Q4 25 | $34.9M | — | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $10.2M | — | ||
| Q1 25 | $4.7M | $-39.7M | ||
| Q4 24 | $66.5M | $-32.2M | ||
| Q3 24 | $43.4M | $-24.9M | ||
| Q2 24 | $8.1M | $38.8M | ||
| Q1 24 | $8.1M | $-26.4M |
| Q4 25 | 133.3% | — | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 40.4% | — | ||
| Q1 25 | 19.8% | -192.9% | ||
| Q4 24 | 287.5% | -86.2% | ||
| Q3 24 | 166.0% | -127.3% | ||
| Q2 24 | 39.6% | 41.0% | ||
| Q1 24 | 32.3% | -44.6% |
| Q4 25 | 4.0% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 1.2% | 5.6% | ||
| Q4 24 | 5.3% | 1.7% | ||
| Q3 24 | 0.3% | 3.3% | ||
| Q2 24 | 0.2% | 1.1% | ||
| Q1 24 | 0.6% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | -27.94× | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | 0.72× | ||
| Q1 24 | 1.41× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
